Compare Invesco Ltd. (IVZ) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Koninklijke Philips NV — how do they compare? Invesco Ltd. trades at $29.73 (market cap $13.28B), while Koninklijke Philips NV trades at $24.32 (market cap $23.52B). The key difference: Koninklijke Philips NV is the larger of the two by market cap, and Koninklijke Philips NV pays the higher dividend (4.17%). Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Koninklijke Philips NV for 84 Days on average.
| IVZ | PHG | |
|---|---|---|
Market Cap | $13.28B | $23.52B |
Volume | 3,698,033 | 1,635,069 |
Sector | Financials | Health |
52-Week High | $33.31 | $32.91 |
52-Week Low | $22.44 | $23.81 |
Typical Hold Time | 77 Days | 84 Days |
Enterprise Value | $23.45B | $29.87B |
Dividend Yield | 2.86% | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $30.50, up 0.39% on the day, with a mixed technical outlook showing bearish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $281.7 million for 2025 despite revenue growth to $6.38 billion, with profitability metrics like ROE at -2.97% indicating challenges. Recent news highlights the expansion of its QQQ ETF suite and a dividend declaration, while analyst consensus remains cautiously optimistic with a $33.71 price target.
The outlook for IVZ hinges on reversing negative earnings trends and capitalizing on ETF growth initiatives. Key opportunities include strong asset under management growth and product innovation, but risks persist from competitive pressures and market volatility. Investors should weigh the potential for operational improvement against ongoing profitability concerns.
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
